Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...

Cassava Sciences (SAVA) stock faces uncertainty after a major late-stage trial setback for the company's Alzheimer's candiate ...

Cassava Sciences' Alzheimer's drug simufilam failed key trial endpoints, leading to a stock plunge. See why SAVA stock is at risk of delisting or merger.

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...

Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.

Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...

H.C. Wainwright analyst Vernon Bernardino downgraded Cassava Sciences (SAVA) to Neutral from Buy without a price target after the company ...

That was the case this morning with once high-flying stock Cassava Sciences (SAVA). This is a stock that once skyrocketed to $146. A little over three years later, this thing closed the day at $4.30, ...

Cassava Sciences announced that the phase 3 trial of its Alzheimer's drug, simufilam, did not meet its primary endpoints.

Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...

NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

The Biden administration is proposing a major expansion of how Medicare and Medicaid cover Wegovy and Zepbound ...